Arbutus Biopharma Corporation
ABUS
|
$2.97
4.1K
|
Health Technology
(0.0% 1d) (16.9% 1m) (1.4% 1y) (0.0% 2d) (0.0% 3d) (-0.3% 7d) (444.29% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 533,091,831
http://www.arbutusbio.com
Sec Filling | Patents | 80 employees
(US) Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.
hepatitis injection
add to watch list Paper trade email alert is off
Press-releases
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
Published: 2024-04-04 (Crawled : 12:30) - globenewswire.com
MRNA S | $103.86 -1.22% -1.23% 7.4K
|
Health Technology
|
| O: 1.46%
H: 3.2%
C: -0.41%
ABUS | $2.97 4.1K
|
Health Technology
|
| O: 16.73%
H: 6.14%
C: 2.39%
patent construction biopharma ongoing
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
Published: 2024-03-20 (Crawled : 12:00) - globenewswire.com
ABUS | $2.97 4.1K
|
Health Technology
|
| O: -1.58%
H: 3.05%
C: 2.41%
year update financial results
Lipid-Nanoparticle Based Genomic Medicines Market worth $32.5 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
Published: 2024-03-18 (Crawled : 14:00) - prnewswire.com
CVAC | $2.65 -8.94% -8.18% 53K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.73%
BNTX | $87.89 1.63% 1.59% 6.2K
|
Health Technology
|
| O: 0.48%
H: 1.18%
C: 0.08%
ABUS | $2.97 4.1K
|
Health Technology
|
| O: 0.38%
H: 0.38%
C: -3.42%
report genomic market
Arbutus to Participate in Two Upcoming Investor Conferences
Published: 2024-03-08 (Crawled : 12:30) - globenewswire.com
ABUS | $2.97 4.1K
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
Arbutus to Participate in Two Upcoming Investor Conferences - March 8, 2024
Published: 2024-03-08 (Crawled : 14:30) - biospace.com/
ABUS | $2.97 4.1K
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Published: 2024-02-29 (Crawled : 12:30) - globenewswire.com
ROIV | $10.84 -0.91% -0.83% 1.2K
|
Manufacturing
|
| O: 1.2%
H: 0.34%
C: -3.46%
ABUS | $2.97 4.1K
|
Health Technology
|
| O: -1.37%
H: 0.0%
C: -2.44%
year update financial results
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
Published: 2024-02-15 (Crawled : 12:30) - globenewswire.com
ABUS | $2.97 4.1K
|
Health Technology
|
| O: 0.85%
H: 0.0%
C: -1.36%
report year update financial results
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
Published: 2024-01-08 (Crawled : 13:00) - globenewswire.com
ABUS | $2.97 4.1K
|
Health Technology
|
| O: 3.32%
H: 3.21%
C: -1.61%
update financial
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
ABUS | $2.97 4.1K
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: -3.28%
hbv003 biopharma collaboration trial
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
ABUS | $2.97 4.1K
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: -3.28%
vtp-300 meeting liver biopharma trial
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 28% | 72% |
Top 10 Gainers
AMPL | $9.83 2.08% 2.7K
|
CL | $86.445 0.32% 43K
|
Consumer Non-Durables
AESI | $22.105 0.11% 4.7K
|
n/a
AJG | $232.2 0.05% 11K
|
Finance
BCAB | $2.86 3.6K
|
DTE | $105.365 -0.15% 5.1K
|
Utilities
AME | $178.705 -0.19% 9.1K
|
Producer Manufacturing
APO | $107.295 -0.27% 24K
|
Finance
EQNR | $27.64 -0.5% 23K
|
Energy Minerals
BNL | $14.375 -0.59% 7.4K
|
Finance
Last 48 Hours Insiders Buying
RMCF | $3.6492 2.51% -7.2% 0
|
Consumer Non-Durables
|
20:10